Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2017/5074891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549284229152768 |
|---|---|
| author | Munish Sharma Daniel A. N. Mascarenhas |
| author_facet | Munish Sharma Daniel A. N. Mascarenhas |
| author_sort | Munish Sharma |
| collection | DOAJ |
| description | Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication. |
| format | Article |
| id | doaj-art-0f326c22472347758de0741496891a79 |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-0f326c22472347758de0741496891a792025-02-03T06:11:41ZengWileyCase Reports in Cardiology2090-64042090-64122017-01-01201710.1155/2017/50748915074891Ticagrelor Associated Heart Block: The Need for Close and Continued MonitoringMunish Sharma0Daniel A. N. Mascarenhas1Internal Medicine, Easton Hospital, Easton, PA, USADrexel University College of Medicine, Philadelphia, PA, USATicagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic and nonfatal to the patient. We present a case of ticagrelor related second-degree type II heart block causing severe dizziness and diaphoresis that resolved after discontinuation of the medication.http://dx.doi.org/10.1155/2017/5074891 |
| spellingShingle | Munish Sharma Daniel A. N. Mascarenhas Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring Case Reports in Cardiology |
| title | Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring |
| title_full | Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring |
| title_fullStr | Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring |
| title_full_unstemmed | Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring |
| title_short | Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring |
| title_sort | ticagrelor associated heart block the need for close and continued monitoring |
| url | http://dx.doi.org/10.1155/2017/5074891 |
| work_keys_str_mv | AT munishsharma ticagrelorassociatedheartblocktheneedforcloseandcontinuedmonitoring AT danielanmascarenhas ticagrelorassociatedheartblocktheneedforcloseandcontinuedmonitoring |